Novartis and Biofourmis seek to pinpoint early signs of heart failure exacerbations and steer treatments leveraging Biovotion wearables. Previously, Biofourmis was device agnostic, incorporating a variety of wearable tech into its digital therapies — but the buy will afford Biofourmis access to a bevy of new data via Biovotion's armband, dubbed Everion, which can power its predictive analytics platform.
The wealth of data the Biofourmis product can collect could fuel more personalized treatments and clamp down on skyrocketing costs for heart failure patients. Patients taking Novartis' heart failure drug Entresto will strap on the Everion wearable and use Biofourmis' AI-powered heart failure platform to monitor their symptoms and manage their meds.
The platform uses these insights to predict and analyze patients' drug treatments. The product will accrue a bulk of comprehensive data that could personalize therapies for a swelling population of heart failure patients: In the US alone, the number of patients afflicted by the condition is expected to balloon from about 5.
The team-up could shed some light on what types of DTx partnerships might be most worthwhile to pharma companies. Over the last few years, we have seen pharma companies demonstrating interest in the
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »